Vervet Logic, Inc. is the developer of VervetX, a platform designed to simplify the development and deployment of complex event-driven applications. The company focuses on providing a low-code/no-code environment that enables users to create, test, and run event-driven architectures with ease.

Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts. 

Eli Lilly

Wellington Management

Janus Henderson Investors

Logos Capital

Google Ventures

Biomatics Capital Partners

Casdin Capital

Novo Holdings

RA Capital Management

Redmile Group

Cormorant Asset Management

Verve Therapeutics

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics, Inc.

COM:VERVETX

Vervet Logic, Inc.

Last Close

4.55

21/11 19:28

Market Cap

507.99M

Beta: -

Volume Today

722.02K

Avg: -

Analysis Not Available